Melatonin Newbury

Melatonin, the active ingredient in Melatonin Newbury, is a melatonin receptor agonist presented as an oral dosage form for oral use. It originates from the European Union market and is formulated to meet quality standards, helping regulate the sleep‑wake cycle and address sleep disturbances in adults.

GNH USA supplies Melatonin Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide, providing reliable sourcing for healthcare providers across multiple regions.

Melatonin acts on the melatonin receptors that regulate the circadian rhythm and is used for several sleep‑related conditions.

Insomnia: assists adults in reducing sleep onset latency and improving sleep continuity. Jet lag: helps travelers adjust their internal clock after rapid east‑west or west‑east travel. Shift work disorder: supports sleep timing for individuals working non‑standard hours. Delayed sleep phase disorder: advances sleep onset in people with a delayed circadian phase.

Melatonin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Dizziness - Daytime sleepiness - Nausea - Mild gastrointestinal upset - Vivid dreams

Serious or Rare Side Effects: - Allergic reactions such as rash or angioedema - Severe hypersensitivity requiring medical attention - Mood alterations including depression or agitation - Rare seizures - Hormonal disturbances, e.g., menstrual irregularities

When considering melatonin therapy, several safety points should be observed. - Pregnancy: safety not established; use only if clearly needed and prescribed. - Breastfeeding: insufficient data; weigh potential benefits against risks. - Concomitant CNS depressants: may increase sedation; monitor patient response. - Elderly patients: start with the lowest effective dose and assess tolerance. - Autoimmune conditions: monitor for possible disease activity changes. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Melatonin may interact with other medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Immunosuppressants (e.g., cyclosporine): potential reduction in immunosuppressive effect. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): can raise melatonin plasma concentrations.

Moderate Interactions (Monitor Closely): - Sedatives (benzodiazepines, Z‑drugs): additive drowsiness. - Antidepressants (SSRIs, SNRIs): possible alteration of sleep architecture. - Oral contraceptives: may increase melatonin levels, requiring observation.